You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1149-ESGO Oxaliplatin-based treatments are currently a valid therapeutic option in heavily pretreated ovarian cancer patientswith hypersensitivity reactions (HRs) to carboplatin in the antiangiogenics and PARPi era
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to October 2024

AbstractFullPdf
Oct 2022401
Nov 20222202
Dec 20227809
Jan 20232101
Feb 20231701
Mar 2023801
Apr 20231002
May 20231400
Jun 2023400
Jul 20231303
Aug 2023602
Sep 2023202
Oct 2023802
Nov 20231502
Dec 20232502
Jan 2024602
Feb 2024804
Mar 20241603
Apr 20241603
May 20241304
Jun 20242003
Jul 2024402
Aug 2024504
Sep 2024701
Oct 2024800
Total350056